Sunday, January 19, 2020 9:13:22 AM
It's in the SEC fine tooth comb division.
I'll paste it again.
(c) On June 25, 2019, the Registrant appointed Justin Costello, age 38, Director, President and Chief Executive Officer. No family relationship existed pertinent to the Registrant’s appointment of Mr. Costello as President and Chief Executive Officer. Mr. Costello is a graduate of the Winona State University in 2003 in Public Administration and attended Harvard University, but did not graduate. Mr. Costello manages and is the Chief Executive Officer of GRN Funds, LLC, a private equity and capital management company. Mr. Costello has not held any other directorships during the past five years in any company with a class of securities registered pursuant to section 12 of the Exchange Act, or subject to the requirements of section 15(d) of such Act, or any company registered as an investment company under the Investment Company Act of 1940, 15 U.S.C. 80a-1, et seq., as amended.
I'll paste it again.
(c) On June 25, 2019, the Registrant appointed Justin Costello, age 38, Director, President and Chief Executive Officer. No family relationship existed pertinent to the Registrant’s appointment of Mr. Costello as President and Chief Executive Officer. Mr. Costello is a graduate of the Winona State University in 2003 in Public Administration and attended Harvard University, but did not graduate. Mr. Costello manages and is the Chief Executive Officer of GRN Funds, LLC, a private equity and capital management company. Mr. Costello has not held any other directorships during the past five years in any company with a class of securities registered pursuant to section 12 of the Exchange Act, or subject to the requirements of section 15(d) of such Act, or any company registered as an investment company under the Investment Company Act of 1940, 15 U.S.C. 80a-1, et seq., as amended.
Recent MAJI News
- NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test • GlobeNewswire Inc. • 04/07/2026 02:30:00 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/30/2026 04:15:02 AM
- Form 253G1 - • Edgar (US Regulatory) • 03/27/2026 07:12:08 PM
- Form 1-A POS - • Edgar (US Regulatory) • 03/26/2026 08:25:15 PM
- Form 1-A POS - • Edgar (US Regulatory) • 03/20/2026 08:23:33 PM
- Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value • GlobeNewswire Inc. • 03/16/2026 02:15:00 PM
- Form 1-A POS - • Edgar (US Regulatory) • 03/11/2026 07:11:39 PM
- Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions • GlobeNewswire Inc. • 03/05/2026 06:00:20 PM
- Form 1-A POS - • Edgar (US Regulatory) • 02/19/2026 09:39:04 PM
- Form 253G2 - • Edgar (US Regulatory) • 02/11/2026 08:06:08 PM
- Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition • GlobeNewswire Inc. • 02/10/2026 03:30:00 PM
- Form 253G2 - • Edgar (US Regulatory) • 01/15/2026 06:47:01 PM
- Form 253G1 - • Edgar (US Regulatory) • 01/14/2026 09:54:45 PM
- Form 1-A POS - • Edgar (US Regulatory) • 12/31/2025 12:32:47 PM
- Form 253G2 - • Edgar (US Regulatory) • 12/29/2025 08:29:49 PM
- Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization • ACCESS Newswire • 12/11/2025 05:15:00 PM
- Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement • ACCESS Newswire • 12/05/2025 04:00:00 PM
- Form 253G2 - • Edgar (US Regulatory) • 12/04/2025 09:35:28 PM
- Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms • ACCESS Newswire • 12/02/2025 06:45:00 PM
- Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value • ACCESS Newswire • 11/17/2025 08:40:00 PM
- Exousia Pro Announces Breakthrough In Exosome-Based Delivery • ACCESS Newswire • 11/04/2025 03:40:00 PM
- Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA • ACCESS Newswire • 10/28/2025 02:20:00 PM
- Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes • ACCESS Newswire • 09/29/2025 04:35:00 PM
- Exousia Pro Reports Positive Outcome in Legal Proceeding • ACCESS Newswire • 09/26/2025 02:30:00 PM
